TP53 and liposarcoma: The therapeutic strategy of disrupting the MDM2-p53 interaction has led to the development of multiple targeted agents, some of which have shown encouraging results in preclinical and early clinical trials, particularly in tumors with wild-type TP53, such as dedifferentiated liposarcoma and certain hematologic malignancies.